Short Interest in Ono Pharmaceutical Co., Ltd. (OTCMKTS:OPHLY) Decreases By 25.6%

Ono Pharmaceutical Co., Ltd. (OTCMKTS:OPHLY) was the target of a significant decline in short interest during the month of February. As of February 28th, there was short interest totalling 30,200 shares, a decline of 25.6% from the February 13th total of 40,600 shares. Based on an average daily trading volume, of 765,800 shares, the days-to-cover ratio is presently 0.0 days.

Ono Pharmaceutical Stock Performance

Shares of Ono Pharmaceutical stock traded up $0.00 during trading on Monday, reaching $3.68. The company’s stock had a trading volume of 205,942 shares, compared to its average volume of 458,863. The stock has a 50-day moving average price of $3.46 and a two-hundred day moving average price of $3.88. Ono Pharmaceutical has a one year low of $3.21 and a one year high of $5.67.

Ono Pharmaceutical Company Profile

Ono Pharmaceutical Co, Ltd., together with its subsidiaries, produces, purchases, and sells pharmaceuticals and diagnostic reagents worldwide. It offers Opdivo Intravenous Infusion and Kyprolis Intravenous Injection for malignant tumors; Emend capsules/Proemend intravenous injections for chemotherapy-induced nausea and vomiting; Demser capsules for the symptoms in patients with pheochromocytoma; and Mektovi, Velexbru, and Braftovi capsules for malignant tumors, as well as ADLUMIZ tablets for cancer cachexia.